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Introduction
The advent of imatinib mesylate has revolutionized the treatment of patients with chronic myeloid leukemia (CML). 1 After the 7-year follow-up of the IRIS study, the estimated overall survival of patients who received imatinib as initial therapy was 86% and freedom from progression to accelerated phase or blast crisis was 93%. 2 However, a minority of patients in chronic phase and a substantial proportion of patients in advanced phases of CML are either initially refractory to imatinib treatment or lose sensitivity to imatinib over time and thereby experience relapse. 3 The most frequently identified mechanism of acquired imatinib resistance is the emergence of point mutations within the BCR-ABL kinase domain impairing imatinib binding either by interference with the imatinib binding site or by stabilizing a BCR-ABL conformation with reduced binding affinity for imatinib. 4 To date, more than 70 different BCR-ABL kinase domain mutations, encoding for more than 50 different amino acid substitutions, have been described in imatinib-resistant CML patients. 5 Various techniques have been employed to detect BCR-ABL kinase domain mutations, resulting in different reported frequencies of mutations and the finding of a heterogeneous pattern of individual mutations. There is currently no consensus concerning the technique that should be used for routine monitoring of CML patients and there are still difficulties in clinical interpretation of specific mutations. One particularly reliable and sensitive approach is the selection and expansion of specific clones followed by DNA sequencing. 6, 7 However, this procedure is cumbersome and not suitable for routine clinical analysis. As an alternative, sequencing of nested polymerase chain reaction (PCR)-amplified BCR-ABL products has been widely used to search for known and unknown BCR-ABL kinase domain mutations. 8, 9 A potential drawback of direct sequencing (DS) is its detection sensitivity of only 10-20%. In comparison, sensitivities of 1-5% can be obtained using denaturing high-performance liquid chromatography (D-HPLC), [10] [11] [12] [13] doublegradient denaturing electrophoresis, 14 pyrosequencing, 15 high-resolution melting, 16 or array-based assays. 17, 18 More sensitive methods include peptide nucleic acid-based PCR clamping 19 and allele-specific oligonucleotide (ASO) PCR. [20] [21] [22] [23] However, these techniques are specific for known mutations and cannot be applied for screening of unknown mutations. To date, these methods have been used for scientific purposes -such as quantification of low-level drug resistance -rather than clinically relevant monitoring of drug-resistant clones. A comparative assessment of technical features characterizing individual detection techniques has not been performed to date.
In this study we sought to compare different techniques for the detection of BCR-ABL kinase domain mutations in CML patients after imatinib failure. Serial blinded samples from patients on second-generation tyrosine kinase inhibitor (TKI) therapy were simultaneously analyzed using two screening methods (DS and D-HPLC in combination with DS) and two high-sensitivity ASO PCR techniques: an amplification refractory mutation system (ARMS) PCR and ligation-PCR (L-PCR). In particular, we sought to evaluate (i) the reliability of D-HPLC/DS results compared to DS and (ii) whether ASO PCR-based genotyping approachesdespite their obvious drawback of detecting known mutations only -confer a clinically advantageous level of sensitivity of mutation detection which eventually could justify implementation of these techniques in clinical monitoring of CML patients.
Design and Methods

Patients' samples
In total, 200 blood samples from 40 BCR-ABL-positive CML patients with treatment failure or suboptimal response to imatinib according to the European LeukemiaNet recommendations 24 were investigated. All patients gave written informed consent, had previously received between 400 and 800 mg imatinib/day and were included in the clinical trials NCT00109707, NCT00384228, CA180013, CA180005 and CA180006 (www.clinicaltrials.gov). These trials were conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000, and approved by national and/or international ethics committees. The patients' characteristics are given in Table 1 . Mutation analysis was performed prior to start of second-line TKI therapy with dasatinib 140 mg/day (n=20) or nilotinib 800 mg/day (n=20) and after 3, 6, 9, and 12 months on therapy. Patients were randomly selected and samples were blinded in the Mannheim (Germany) laboratory. Two hundred cDNA aliquots were shipped to each of the other two participating laboratories in Leipzig (Germany), and Tromsø (Norway).
RNA extraction and cDNA synthesis
Total RNA was extracted after hypotonic red cell lysis from at least 20 mL of peripheral blood using the RNeasy ® Mini Kit (Qiagen, Hilden, Germany) or TRIzol ® reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturers' instructions. Complementary DNA synthesis was performed using random hexamer primers and MMLV reverse transcriptase (Invitrogen) as described elsewhere. Quantitative reverse-transcriptase polymerase chain reaction BCR-ABL, total ABL and β-glucuronidase (GUS) transcripts were amplified in Mannheim using the LightCycler TM technology (Roche Diagnostics, Mannheim, Germany) and detected via specific hybridization probes as described previously. 26, 27 The control genes were selected based on recommendations of the Europe Against Cancer (EAC) protocol. 28 Two microliters of cDNA were used as the template for the quantitative reverse transcriptase-PCR reactions.
Direct sequencing
DS was performed in Tromsø as described previously. 9 Hemi-nested PCR products of 675 bp encoding amino acids 207-414 were amplified and sequenced in both directions using an ABI PRISM ® 3130 Genetic Analyzer and the BigDye Terminator kit version 3.1 (Applied Biosystems, Foster City, CA, USA). Sequences were compared with the wild-type ABL sequence (GenBank accession no. U07563). In our hands this approach allows the detection of mutations if the mutated transcripts represent at least 20% of the entire BCR-ABL transcriptome using mutant BaF/3 cell line dilution series.
Denaturing high-performance liquid chromatography in combination with direct sequencing D-HPLC was performed in Mannheim on a Transgenomic Wave TM System Model 3500 HT (Transgenomic, Omaha, NE, USA) according to previous descriptions. 13 This technique is based on heteroduplex formation by PCR products amplified from wild-type and mutant alleles and allows high throughput screening applications. Briefly, three overlapping fragments covering the entire BCR-ABL kinase domain (amino acids 207 through 517) were generated by nested PCR and analyzed for the presence of sequence variations by D-HPLC. PCR products with an abnormal D-HPLC profile were sequenced in both directions to characterize the precise nucleotide substitution(s) and compared to the ABL wild-type sequence (GenBank accession no. U07563). Growth factor-independent Ba/F3 cell populations expressing full-length non-mutated BCR-ABL or full-length BCR-ABL with the clinically most common BCR-ABL kinase domain mutations Y253F, E255K, T315I or M351T were used to optimize the D-HPLC assay and to estimate its sensitivity. Using serial dilutions the detection limit for T315I and M351T mutations was estimated as 0.1%, whereas the limits for the Y253F and E255K mutations were 0.5% and 1%, respectively. Selected mutant and non-mutant Ba/F3 cell lines were used as internal controls for each D-HPLC run. ABL single nucleotide polymorphisms were identified as described previously and excluded from this study.
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Amplification refractory mutation system polymerase chain reaction ARMS PCR was performed in Tromsø according to previous descriptions. 21 Complementary DNA corresponding to 80 ng RNA was subjected to a single step of PCR amplification (95°C 10 for min, 50 cycles of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 min) using assays which were optimized for selective amplification of mutations known to confer TKI resistance [total volume 25 µL, 2x master mix (Eurogentec, Brussels), 1 µM Taqman probe, 2 µM primers, Mx3000P real time platform (Stratagene, La Jolla, CA, USA)]. Briefly, primers were chosen to complement the mutated allele at the 3'-end. For the purpose of increased affinity the primers contained additional mismatches allowing a preferential amplification of the mutated template over an almost 4-log range. Samples giving rise to amplification curves crossing a threshold significantly earlier compared to curves derived from non-mutant Ba/F3 cells were classified as positive. The resulting Ct values were subsequently translated into copy numbers after comparison to standard curves derived from amplification of a 10-fold diluted plasmid containing the respective mutation (pCR 2.1 vector, linearized with HindIII). For normalization, copy numbers were finally related to total BCR-ABL and expressed as BCR-ABL mutant /BCR-ABL total . This single step approach has previously been shown to detect mutated transcripts if they contribute at least 0.1% of the total BCR-ABL and ABL transcript count.
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Ligation polymerase chain reaction L-PCR was performed in Leipzig as described previously. 23 In addition to the already described hybridization, ligation, and quantification procedures to detect BCR-ABL T315I and BCR-ABL
E255K
, additional hybridization probes were used for the remaining mutations (Online Supplementary Table S1 
Statistical analysis
Since DS and D-HPLC/DS led to dichotomous results (mutation detection yes or no), the scaling of both parameters was always categorical. In general, BCR-ABL/ABL and BCR-ABL/GUS ratios as well as the various mutation levels measured by ARMS or L-PCR are given as continuous data. If frequencies of mutation detection were compared between the methods, results of ARMSand L-PCR were dichotomized (mutation detection yes or no) as well. To assess the relation between two categorical variables, Fisher's exact test was applied. Groups with continuous data were compared by the MannWhitney U test. The association between two continuous parameters was described by the Spearman's rank correlation coefficient. Due to the explorative nature of the analyses, the level of statistical significance was 0.05 for all tests. Only two-sided p values were recorded. All calculations were performed using SAS/STAT software, Version 9.1.3 for PC.
Results
BCR-ABL/ABL and BCR-ABL/GUS ratios
BCR-ABL fusion mRNA was quantified and related to the expression of two reference genes prior to and at 3-monthly intervals during second-line dasatinib (n=20) or nilotinib (n=20) therapy. Median BCR-ABL/total ABL and BCR-ABL/GUS ratios were 90% (range, 5.5-260%) and 21% (range, 0.56-128%) in patients prior to dasatinib therapy. After 12 months of dasatinib therapy, BCR-ABL/total ABL and BCR-ABL/GUS ratios were reduced to 4.5% (range, 0-71%) and 2.1% (range, 0-34%), respectively. Median BCR-ABL/total ABL and BCR-ABL/GUS ratios were 56% (range, 11-100%) and 17% (range, 4.8-109%) in patients prior to nilotinib therapy. After 12 months of nilotinib therapy, BCR-ABL/total ABL and BCR-ABL/GUS ratios were reduced to 8.2% (range, 0-81%) and 2.9% (range, 0-65%), respectively.
Analyzed samples and number of detected mutations
In total, 174 of 200 samples (87%) were comparable between the different mutation detection approaches. The remaining 26 samples had a BCR-ABL/total ABL ratio <0.1% on second line TKI therapy and the amplification of BCR-ABL failed in at least one laboratory. Table 2 gives an overview of all mutations detected by the four different methods in regard to the underlying second-line TKI therapy. In total, 667 mutations were identified (DS, n=114; D-HPLC/DS, n=142; ARMS, n=191; L-PCR, n=220). 
Comparison of amplification refractory mutation system-and ligation-polymerase chain reaction
The 187 mutations not found by DS and/or D-HPLC/DS are here referred to as low-level mutations ( Figure 2B ). Sixty-two of these 187 mutations (33%) were independently detected by ARMS and L-PCR [G250E (n=4), Q252H (n=1), Y253H (n=9), E255K (n=15), E255V (n=1), V299L (n=3), T315I (n=12), F317L (n=9), M351T Of these 125 mutations, 48 (38%) were detected by ARMS only: G250E (n=6), Q252H (n=1), Y253H (n=7), E255K (n=4), V299L (n=5), T315I (n=6), F317L (n=9), M351T (n=8), F359V (n=2). The other 77 (62%) were detected by L-PCR only: Q252H (n=1), Y253H (n=7), E255K (n=4), E255V (n=2), V299L (n=1), T315I (n=40), F317L (n=8), M351T (n=5), F359V (n=9). Differences in the number of detected mutations between ARMS and L-PCR were significant for the T315I mutation only (p<0.0001, Fisher's exact test).
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Baseline (month 0) Dasatinib (months 3-6-9-12) Nilotinib (months 3-6-9-12) D-HPLC/DS ARMS L-PCR D-HPLC/DS ARMS L-PCR D-HPLC/DS ARMS L-PCR
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--: not investigated by the respective method; D-HPLC/DS: D-HPLC in combination with direct sequencing; ARMS: amplification refractory mutation system PCR; L-PCR: ligation-PCR.
DS D-HPLC/DS ARMS L-PCR
DS: direct sequencing; D-HPLC/DS: D-HPLC in combination with direct sequencing; ARMS: amplification refractory mutation system PCR; L-PCR: ligation-PCR.
Evaluation of the diagnostic window for emerging drug-resistant clones and follow-up of pre-existing clones
We examined whether or not the greater sensitivity of ASO PCR could be exploited for clinically relevant purposes. Two categories of mutant clones were investigated: (i) clones harboring baseline mutations which disappeared according to D-HPLC/DS during second-line TKI treatment (n=10); and (ii) clones emerging by D-HPLC/DS upon second-line TKI treatment (n=15). ASO PCR detection of these clones was compared to D-HPLC/DS detection in serial samples (Figure 3 ). ARMS allowed a median 6 months (range, 0-9 months) longer follow-up of pre-existing clones than did D-HPLC/DS. By L-PCR, pre-existing mutant clones were traceable for a median of 3 months (range, 0-9 months) longer. Regarding clones emerging during treatment, both ASO PCR techniques detected mutant clones a median of 3 months (range, 0-12 months) earlier than did D-HPLC/DS. Overall, pre-existing mutations were traceable for a median of 4.5 months longer and emerging clones were detectable 3.0 months earlier by ASO PCR than by D-HPLC/DS.
Association of detected mutations and clinical characteristics
All mutational findings of DS, D-HPLC/DS, ARMS and L-PCR at the four study time points (months 3, 6, 9, and 12) were correlated with the clinical characteristics, disease phase, second-line TKI treatment (dasatinib or nilotinib), and a BCR-ABL/total ABL level ≤0.1% at 12 months. Only F317L findings showed associations with clinical characteristics. One F317L mutation had been identified by D-HPLC/DS at baseline but was only detectable by ARMS and L-PCR at 3 months and became undetectable thereafter during nilotinib therapy by all techniques. In contrast, four patients on dasatinib (chronic phase, n=1; accelerated phase, n=2; myeloid blast crisis, n=1) but no patient on nilotinib showed a F317L mutation after 12 months by D-HPLC/DS (p=0.0392, Fisher's exact test). Each of these mutations was already detectable by at least one of the ASO PCR techniques at a low level at baseline and became detectable by D-HPLC/DS after 3 (n=2), 6 and 9 months, respectively. However, more data are needed for a satisfactory investigation of the influence of an interaction between treatment and progression on the development of a F317L mutation. 
Discussion
Since the introduction of imatinib and the discovery of BCR-ABL kinase domain mutations as the main mechanism of resistance, mutation detection in the case of treatment failure or suboptimal response has become an increasingly important issue in the management of CML patients. 24 With the availability of second-generation TKI with different in vitro 4, 5 and in vivo 30, 31 activity against mutant clones, the presence of mutations provides information relevant to the selection of the optimal second-or third-line treatment. However, a range of different screening and mutation detection techniques has been employed. Here, we present a blinded comparison of D-HPLC screening followed by DS and DS alone initiated by investigators of the European LeukemiaNet. Consistent with the higher sensitivities expected from the smaller PCR fragments amplified in D-HPLC/DS, we detected 13 additional mutations (+11.4%) by this technique. However, only four of these samples were diagnosed as wild-type by DS alone. Thus, in our study the higher sensitivity of D-HPLC/DS resulted mainly in the detection of second or third mutated clones (n=9). However, D-HPLC/DS has some additional advantages: first, the initial screening for mutations by D-HPLC has proven to be more rapid and cost-effective in our hands than the full procedure of DS. Second, the three overlapping fragments effectively cover the entire BCR-ABL kinase domain (amino acids 207-517) compared with the two fragments (amino acids 207-414) analyzed by DS. Taken together, in our study both techniques were suitable and closely comparable for the detection of major resistant clones in cases of resistance or suboptimal response to TKI treatment in CML. Since there are other techniques available with different laboratory-specific modifications and applications, this study provides a basis for further comparisons and standardization efforts comparable with the introduction of the international scale for quantification of BCR-ABL transcripts. 32 Another aim of our study was to perform a blinded comparison of D-HPLC/DS vs. two ASO PCR techniques which are currently experimental but potentially more sensitive and quantitative. So far, these techniques have been employed not for mutation screening, but rather to follow known mutated clones over time (ARMS) 21 or to provide accurate quantification of specific mutant clones (L-PCR). 23 Taking the mutations detected by D-HPLC/DS as a high level reference, both ASO PCR techniques showed a low false negative rate, missing only two of 83 mutations (2.4%). Among the mutations detected by both ASO PCR and D-HPLC/DS, the lowest proportion quantified by ASO PCR was 0. we can largely exclude false positive results for both ASO PCR techniques. Given that the implications for high sensitivity and quantitative mutation testing in the specific management of CML patients are unknown, we considered: (i) whether we could identify associations with clinical characteristics, and (ii) whether we were able to increase the diagnostic window for detection of emerging or preexisting clones prior to progression.
Due to the fact that this study was set up with the primary aim of comparing different techniques, only a limited number of patients and clinical characteristics were available. However, we observed more emerging F317L mutant clones on dasatinib therapy (n=4) than on nilotinib therapy (n=0) within 12 months. All of these F317L clones were already detectable at a very low level by the ASO PCR techniques prior to initiation of dasatinib. Furthermore, we observed an association of F317L mutations and advanced disease phase, as previously reported. 33 The low number of patients with F317L did not enable a test for independency of these two characteristics. Therefore, more data are needed to investigate the interaction between advanced disease phase, dasatinib treatment and the occurrence of a F317L mutation as well as the additional role of high sensitivity mutation testing.
As reported for the specific D-HPLC/DS technique used in this study, BCR-ABL mutations were detectable a median of 7.1 months prior to hematologic relapse. 13 The ASO PCR techniques might further increase the diagnostic window from 7.1 to 10.1 months, by detecting the G250E, E255K/V, T315I, F317L and F359V mutatios 3 months earlier than D-HPLC/DS can do. Almost all of these mutations have been shown to arise on treatment or have lower response rates to dasatinib (IC50>3 nM; Q252H, E255K/V, V299L, F317L, T315I), or nilotinib (IC50>150 nM; Y253H, E255K/V, F359V/C, T315I). 30, 31 Hence, 3-monthly serial monitoring by D-HPLC/DS for patients on second-line TKI treatment and an unsatisfactory response is likely to be useful. A further increase of the diagnostic window by using more sensitive techniques provides an opportunity for earlier optimization of the TKI therapy and increases the time available for identification of a stem cell donor in those cases in which allogeneic transplantation is an option. Based on the current study, this goal should be achievable by serial monitoring of those mutations at risk on the specific treatment (i.e. IC50>3 nM for dasatinib and IC50>150 nM for nilotinib). It remains to be seen whether threshold levels of mutant clones or the kinetics of increase over time would be most informative in this respect. Based on this study and considering the narrowing spectrum of mutations causing resistance on secondor third-line TKI treatment, we foresee potential advantages for highly sensitive and quantitative monitoring of mutant clones in the future management of CML patients with an unsatisfactory response.
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